# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Mizuho analyst Uy Ear downgrades Avrobio (NASDAQ:AVRO) from Buy to Neutral and lowers the price target from $5 to $2.
Wells Fargo analyst Yanan Zhu maintains Avrobio (NASDAQ:AVRO) with a Overweight and lowers the price target from $2.5 to $2.
Gainers Healthcare Triangle, Inc. (NASDAQ: HCTI) shares climbed 171.2% to $8.84 as the company launched initiative to preven...
Wedbush analyst David Nierengarten downgrades Avrobio (NASDAQ:AVRO) from Outperform to Neutral and announces $2 price target.
AVROBIO Inc (NASDAQ: AVRO) shares are trading higher Wednesday after the company said it will explore strategic alternatives.